NCT07594522
A Study of Ivonescimab in People With Non-Small Cell Lung Cancer
Recruiting · Phase 1, Phase 2 · Memorial Sloan Kettering Cancer Center · registry updated 2026-05-18
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The researchers are doing this study to find out whether ivonescimab after receiving standard stereotactic body radiotherapy (SBRT) is an effective treatment in people with Non-Small Cell Lung Cancer (NSCLC).
Criteria excerpt
- Patients must have pathologically confirmed non-small cell lung cancer
- Early Stage NSCLC Stage IA2 - IIA (tumor size \> 1cm and ≤ 5cm, N0M0), select IIB (tumor size \>5cm and ≤ 7cm, N0M0). Multiple (up to 2) primary lung cancers allowed. Isolated parenchymal recurrences (tumor size ≤ 7cm and up to 2 separate ipsilateral lesions) of initially TanyN0M0 disease.
- ° Note: The determination of two primary NSCLCs will be based on pathologic and genomic differentiation.
- No known sensitizing EGFR or ALK alterations
- Disease amenable to 3, 5 or 8 fraction SBRT as judged by treating radiation oncologist. Tumors that have extensive overlap with the mediastinum for which a more protracted radiotherapy course (i.e. 15 fraction) would be needed are excluded.
- No primary tumor (Gross Target Volume, GTV) that contacts the esophagus